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Yesterday is past,  
tomorrow is future, 
    today is a gift –                                                                                        
     that’s why it´s called PRESENT 








Background: Medial temporal lobe atrophy (MTA) has been found to be an early sign 
of Alzheimer’s disease (AD). Visual assessment of MTA (vaMTA) is a rapid, cost-
efficient and clinically adaptable visual interpretation method for rating MTA, based on 
coronal magnetic resonance imaging (MRI) scans. The method was developed by 
Scheltens et al in the 1990s. 
 
Purpose: The aim of this thesis was to investigate the reliability of vaMTA using the 
Scheltens rating scale: on a long-term basis, compared with volumetric calculation, 
compared with multivariate analyses and, finally, tested in a clinical situation 
 
In Study I, MRI scans of 100 patients were visually assessed six times over a 1-year 
period. Two radiologists, with different backgrounds, performed the assessments 
independently of each other. The results showed a high degree of reproducibility when 
performed by an experienced investigator. The reproducibility drops when assessment 
is rarely performed. 
Study II was a comparison between vaMTA and measurement of hippocampal volume 
in 544 non-demented elderly individuals from the SwedishNational Study of Ageing 
and Care in Kungsholmen (SNAC-K). A significant correlation was found between the 
two methods. Cut-off values for MTA scores in normal ageing were also suggested. 
In Study III the reliability of Scheltens’ visual assessment rating scale for assessing 
MTA was compared with that of a multivariate MRI classification method, orthogonal 
projections to latent structures (OPLS), and manually measured hippocampal volumes 
to distinguish between subjects with AD and healthy elderly controls (CTL).  
A comparison between the different techniques was also performed in predicting future 
developments from mild cognitive impairment (MCI) to AD. The prediction accuracies 
in distinguishing between AD patients and CTL were high for all three modalities. All 
three methods were also highly accurate in identifying subjects who converted from 
MCI to AD at 1-year follow-up. 
Finally, in Study IV, vaMTA scores were used in a validation study of the proposed 
new “Dubois criteria” in Alzheimer’s disease, in which MTA is one of four important 
biomarkers. A retrospective study of 150 patients was carried out to compare the 
traditional diagnostic criteria for dementia with the new criteria suggested by Dubois et 
al. The results showed a lack of accuracy for the new AD criteria, as they were valid for 
only 55% of the clinically diagnosed patients with full-blown AD in this study. 
 
Conclusion: Visual assessment of MTA using the MTA scale is reliable when per-
formed on a daily basis. Medial temporal lobe atrophy scores have a significant 
correlation to hippocampal volume measurements, can predict conversion from MCI to 
AD with similar accuracy as can volumetric calculations and multivariate analysis, and 
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In 1907 Alois Alzheimer was the first to describe both the clinical and pathological 
findings of presenile dementia. As a psychiatrist and a brain researcher specializing in 
neuro histo pathology he received the patient records and brain of a 56-year-old woman 
named Auguste D. He had met the woman years before, as a psychiatrist, and had 
followed her disease progression from a distance. Her symptoms were initially 
described as progressive cognitive impairment, focal symptoms, hallucinations, 
delusions and psychosocial incompetence. At autopsy she was found to have moderate 
hydrocephalus, cerebral atrophy, and arteriosclerosis of the small cerebral vessels. 
Alzheimer described the histopathological findings in the cerebral cortex as “peculiar 
changes in the neurons, with fibrils with characteristic thickness and peculiar 
impregnability”. He also found and described “numerous small miliary foci in the 
superior layer of the cerebral cortex and these foci seemed to be the storage of a 
peculiar material”. Alzheimer wrote a three-page report on this case, titled, “Über eine 
eigenartige Erkrankung der Hirnrinde”, describing the disease that was later named 
after him (1). 
 
A retrospective study of this first medical record of Alzheimer’s dementia, by Maurer 
et al in 1997 (2), confirms the patient’s diagnosis according to the International 
Statistical Classification of Diseases and Related Health Problems, 10th
 
 revision (ICD-
10), criteria for dementia. The miliary foci were later named “senile or neurotic 
plaques” and the intracellular fibrils were called “neurofibrillary tangles”. It was only in 
the 1980s that the plaques were found to be made of beta-amyloid (Aβ) protein and 
neurofibrillary tangles (NFTs) of hyperphosphorylated tau protein (P-tau). 
Since 1907, much research has been done regarding dementia disorders, and the 
research is on-going. In the last 100 years new methods to investigate brain 
degenerative disorders have been given much credit. Research has included areas such 





Dementia, derived from the Latin term de mens, meaning “without mind”, is an 
acquired clinical syndrome of long duration and progressiveness. Dementia is 
forgetfulness (3), but it is also impairment of thinking, reasoning, communication, 
orientation and practical abilities. To learn new things or to maintain learned skills 
becomes difficult. Personality changes resulting in aggressiveness, emotional bluntness, 
lack of insight, judgment and empathy, and disinhibition are other symptoms of 
dementia. 
 
“Dementia” is a general term and does not need to be linked to a specific aetiology. 
Alzheimer’s dementia is only one form of dementia. Other forms of dementia are 
fronto-temporal dementia (FTD), Lewy-body dementia (LBD), vascular dementia 
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(VaD) and mixed dementias. The symptoms and findings vary between these diseases. 
Criteria for dementia are given in the ICD-10 and Diagnostic and Statistical Manual of 
Mental Disorders, 4th
 
 edition (DSM-IV) (3, 4). 
The definitive diagnosis is, despite the increasing use of numerous new biomarkers, 
still a pathological diagnosis. Only at autopsy and using the microscope is the diagnosis 
finally confirmed or rejected.  
 
1.3 MILD COGNITIVE IMPAIRMENT 
Mild cognitive impairment (MCI) is a heterogeneous condition and is said to be a 
transition zone between normal ageing and dementia (5). Mild cognitive impairment 
can convert to dementia and the conversion rate is approximately 12-15%/year. The 
majority of MCI-patients remain stable and about 12% regain normal cognition 
(5,6).Mild cognitive impairment might convert to Alzheimer´s disease, VaD, FTD, 
DLB or mixed dementias (5). 
 
1.4 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) precedes the most common form of dementia, Alzheimer’s 
dementia, and is considered a major threat to public health in the 21st century, world-
wide. Its incidence increases dramatically with age, doubling in frequency every 5 
years after the age of 60, afflicting 1% of all 60–64-year-olds and 30–40% of those 
aged 85 years and older all over the world (6, 7).  
 
Alzheimer’s disease is recognized as a group of diseases, a syndrome, that varies 
according to factors related to age, etiology and heredity. It is a neurodegenerative 
disorder divided into a familial and a sporadic type. The sporadic type of AD is a 
heterogeneous group with multifactorial pathogenesis. Two well-known risk factors 
for sporadic AD are old age and an ε4 allele of apolipoprotein E (ApoE) on chromo-
some 19. The sporadic type of AD represents more than 99% of all cases. Inherited 
familial forms of AD with gene mutations on chromosomes 1, 14 or/and 21 represent 
less than 1 % of all AD cases.  
 
Disease in individuals younger than ≤ 65 years of age is referred to as early-onset or 
presenile AD while AD in individuals ≥65 is referred to as late -onset or senile AD. 
The inherited form of familial AD has the highest representation in early-onset AD. 
The early symptoms of AD are failure in short term memory (episodic memory 
impairment), learning problems and difficulties in processing new information. As 
the disease progresses there is increased speech impairment and a general decline in 
cognitive functions are affected. 
 
The research criteria for AD were outlined in 1984 by the National Institute of Neuro-
logical and Communicative Disorders and Stroke and the Alzheimer’s Disease and 
Related Disorders Association (NINCDS-ADRDA). The NINCDS-ADRDA criteria 
outline the symptoms of the disease and describe the diagnosis of possible, probable, 
and definite AD (8). In possible AD, criteria of dementia must be fulfilled but the 
dementia can be caused by other diseases as well as AD. Probable AD is also based 
on dementia criteria with progressive deterioration of memory and other cognitive 
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functions over time. The diagnosis of definite AD requires histo-pathological 
confirmation at autopsy (8).The clinical diagnostic criteria for AD, used in hospitals, 
are ICD-10 and DSM-IV. 
 
Across the world procedures vary for investigating AD. At Minnesmottagningen, 
Karolinska University Hospital in Huddinge, Sweden the diagnostic work-up is 
performed according to a clinical frame-work including a team of geriatricians, 
neuropsychologists, nurses, occupational therapists and speech therapists headed by a 
senior consultant. The diagnosis is given by a senior consultant in consensus with the 
team-members involved (5). In the clinical frame-work episodic memory is tested 
with Rey Auditory Verbal Learning Test (RAVLT). Two other examples from the 
test-battery are the Mini Mental State Examination (MMSE) and clocktest. Venous 
blood punctures are performed for ordinary and extended check-ups and for APOE ε-
genotyping. Lumbar puncture is performed for liquor analysis albumin, immuno-
globulin G (IgG) and the biomarkers betaamyloid 1- 42 (Aβ-42), total –tau (T-tau) 
and phosphorylated tau (P-tau). An electroencephalogram (EEG) is used to measure 
and record of electrical brain activity. Brain imaging is performed with computed 
tomography (CT) and/or magnetic resonance imaging (MRI), to exclude intracranial 
bleeding, infarctions, tumour and to verify or out-rule brain atrophy. Singlephoton 
emission computed tomography (SPECT) and positron emission tomography (PET) 
can be used for assessment of brain perfusion and cerebral glucose metabolism. 
 
1.4.1 Biomarkers 
The understanding of underlying biological factors of AD has advanced during recent 
years. Biomarkers of different kinds have been recognized and included in the 
assessment. Brain imaging investigations are performed with CT, MRI SPECT and 
PET.  
 
In cerebrospinal fluid (CSF) biomarkers such as Aβ42, T-tau and P-tau can be detected, 
analysed and quantified. Up till now three genetic mutations for AD have been found 
visualized on chromosomes 1, 14 and 21,and can be used as biomarkers of the disease, 
especially in early-onset AD. 
 
1.4.1.1 Brain imaging  
The first CT scanner in Sweden was installed at Karolinska Hospital, Stockholm, in 
1975. Brain imaging with CT has been in public use since around 1980, initially just to 
confirm or rule out intracranial bleeding. The early clinical use of CT in AD 
investigations was primarily to exclude bleeding, tumours and hydrocephalus.  
 
In 1980 one of the first CT studies of normal ageing was performed by Jacoby et al (9). 
In 1982 Soininen et al compared CT findings in demented and non-demented patients 
and found that ventricular dilatation in demented correlated significantly to cognitive 
loss (10).  
 
Today CT is still in use and multidetector-row CT has been shown to be a suitable 
imaging tool to investigate brain atrophy, as an alternative to MRI (11). Two Nobel 
prizes have been won for work in MRI, in 1952 and in 2003. Since 1984 and the 
installation of the first MRI machine in Sweden, at the psychiatric clinic at St Görans 
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Hospital in Stockholm, tremendous developments have taken place in the MRI field. 
The role of MRI in investigating demented patients and especially patients with AD 
was soon recognized (12, 13, 14), with focus on the medial temporal lobe (MTL), 
hippocampus and entorhinal cortex. 
 
Nuclear medicine imaging assesses cerebral perfusion or blood flow with a 
conventional gamma camera using SPECT and gamma-emitting isotopes and evaluates 
impaired glucose metabolism in the brain by means of a PET camera and 18F-fluoro- 
deoxy-glucose (FDG) (15, 16, 17). These methods have been used for almost 30 years 
to evaluate deterioration in the AD brain (18, 19) and FDG is the most evaluated PET 
tracer in AD research. 
 
To increase the specificity of nuclear medicine, imaging tracers reflecting specific 
processes in the AD brain such as amyloid deposition are of interest. The first human 
study with amyloid tracer Pittsburgh compound-B (PIB) was carried out at the Uppsala, 
Sweden, PET centre in collaboration with the Pittsburgh group and was published 
in2004 (20). Pittsburgh compound-B crosses the blood-brain barrier (BBB) and binds 
with high affinity to aggregates of Aβ. Retention of PIB is significantly higher in the 
frontal and temporo-parietal association cortices as well as in striatum in AD patients 
compared with healthy controls (20). Binding of PIB to Aβ is a very early sign in AD 
and when scanning in patients with mild cognitive impairment (MCI), increasing PIB 
retention is seen mainly in those patients who later will convert to AD (21). 
 
1.4.1.2 Cerebrospinal fluid 
Cerebrospinal fluid is in direct contact with the extracellular space in the brain. This 
means that biochemical changes in the brain are reflected in the liquor. Damage to the 
BBB results in high inflammatory cell content and increases albumin concentration. 
High IgG presence in CSF indicates BBB damage and possibly intracerebral 
production of IgG, as seen in neuroinflammatory brain diseases such as multiple 
sclerosis. There are many biomarkers related to AD in the CSF. In clinical practice, 
Aβ42, T-tau and P-tau are used the most. 
 
1.4.1.2.1 
Amyloid beta peptide-42 forms the insoluble main component of the neuritic plaque 
with a length of 42 amino acids after cleavage from amyloid precursor protein (APP). 
Alois Alzheimer saw the plaques in his microscope already in 1907 but not until 1984 
was the protein purified (22). A decrease in Aβ42 content of about 50% is seen in CSF 
in AD patients compared with non-demented controls of the same age. In an autopsy 
study (23) an inverse correlation between Aβ42 levels in CSF and the number of 




The NFT is one of the main neuropathological findings in AD. It is composed of an 
abnormal fibrillar material accumulated in the cytoplasm in large neurons. The main 
component in the NFT is tau protein. 
Tau-protein 
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Tau protein is a microtubule-associated protein normally located in the neuronal axons. 
Its biological functions are to stabilize the microtubule network and regulate axonal 
transport (24). Tau is usually found in six different isoforms (25). All forms can be 
found in the NFT. In AD the tau protein undergoes hyperphosphorylation, which 
affects the normal microtubule binding and stabilization. The NFT is accumulated 
intracellulary in AD, leading to neuronal function loss and cell death. In CSF it is 
possible to analyse the amount of both T-tau and P-tau.  
 
1.4.1.2.3 
All isoforms of tau, irrespective of phosphorylation, are detected and analysed in T-tau. 
Total tau reflects the amount of neuronal degeneration. In AD there is more than 100% 




The amount of P-tau in CSF correlates with the NFT burden in the brain. Phosphory-
lated tau is increased more than 100% in AD compared with controls. 
Phosphorylated tau 
 
In a clinical situation all three CSF markers are tested, even if the combination of Aβ42 
and T-tau is said to have the strongest evidence in the clinical diagnosis of AD 
(27).Sometimes the T-tau/P-tau ratio is used to discriminate other dementias from AD 
(28).Varying laboratory routines, however, make test results difficult to compare 
between centres, making general cut-off levels difficult to establish (27). 
 
1.4.1.3 Genetics  
Genetic predisposition is a well-known risk factor for AD. Families with early age (≤65 
years) at onset of AD were recognized as early as the 1930s (29). Many of those 
families had a clear autosomal dominant inheritance with almost 100% penetrance. The 
association between Down’s syndrome and AD has been known since 1929. In a 
prospective study by Lai and Williams (30) the prevalence of AD in Down’s syndrome 
was 55–75% above 50 years of age. 
 
Most AD cases are late onset. There is no real genetic biomarker in this group. Two 
well-known heavy risk factors for late-onset AD are old age and APOE ε4 (31). 
 
1.4.1.3.1 
Apolipoprotein E has been found to be involved in cholesterol metabolism. The 
encoding apolipoprotein E gene is located on chromosome 19. It consists of three allele 
variants, ε2, ε3 and ε4, with varying frequency across the world. In the Western world 
ε2 occurs in 10%, ε3 in 75% and ε4 in 15% of the population (32). 
Chromosome 19 
 
Two APOE ε4 alleles have been shown to increase the risk of developing AD. It has 
also been reported that presence of two ε4 alleles may lead to early onset of AD (31). 
The APOE gene is a risk factor and not a causative factor for AD. Irrespective of this, 




The APP gene is located on chromosome 21. In 1991 the missing link between AD, Aβ 
and the APP gene was identified as a mutation in the APP gene (33). Since then many 
different mutations have been found in the APP gene, which have been reported to 
account for an estimated 16% of all early-onset AD cases (34). The mutations are  
autosomal dominant and result in malfunction of APP and an excessive Aβ production 




Four years after the discovery of the APP gene mutation, genes on chromosome 14 (36) 
and chromosome 1 (37) were linked to familial AD. They were called presenilin 1 (on 
chromosome 14) and presenilin 2 (on chromosome 1). These two genes have a similar 
genetic structure and encode two highly homologous proteins. Over 170 pathogenic 
mutations of presenilin 1 have been found, and 14 of presenilin 2. These mutations 
commonly result in an increase in the Aβ42/40 ratio (35). The mutations in presenilin 1 
represent about 80% of all early-onset familial AD cases. 
Chromosome 1 and 14 
 
The mutations on the three chromosomes 1, 14 and 21 are all involved in the increase 
of production, deposition and aggregation of Aβ42 in the brain 
 
 
1.5 STRUCTURAL CHANGES IN THE AGEING BRAIN 
A human infant is born with an immature brain. Myelination begins during the fifth 
foetal month and proceeds rapidly up to an age of 2 years. The myelination process 
slows markedly after 2 years of age but continues in fibres of associative brain areas 
up to the third and fourth decade of life (38). Many intervention studies currently 
target adults 60 years of age and older(39), but studies in individuals 18-60 years of 
age have however demonstrated decline of memory as early as in the twenties 
(40)This means that memory decline begins short after reaching maturity and maybe 
even before myelination is completed. 
 
In the normal ageing brain it is possible to detect degenerative changes by CT and 
MRI. Whole brain volume can be calculated using MRI volumetry. By conducting 
repeated investigations over a time period, it is possible to see progression by using 
image subtraction or calculating atrophy progression with volumetry (39, 41). Age-
related ventricular volume expansion, loss of cortical thickness and hippocampal 
volume losses are also possible to subtract or calculate, as is done in longitudinal 
studies (39). The atrophy rate/year can be calculated. In older ages there is an 
acceleration of the atrophy rate and the border between normal ageing and 
pathological ageing may be more difficult to determine. 
 
1.5.1 Medial temporal lobe 
The MTL consists of amygdala, hippocampus, parahippocampal gyrus entorhinal 
cortex, choroid fissure, temporal horn of the lateral ventricle, and the collateral sulcus. 
In AD and other forms of dementias MTA is in focus and has been for a long period of 
time.  
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Staging of AD neuropathology was performed by Braak and Braak in the 1990s (42). 
According to these authors, neuropathological AD changes start in the entorhinal 
cortex. This is also the region were the myelination process ended. The degeneration 
spreads in reverse direction to the myelination process, namely from the transentorhinal 
cortex to entorhinal cortex, to the amygdala and from here to the hippocampus (42, 43, 
44).Primary sensory and motor areas are spared until late in the disease process. Senile 
plaques or neuritic or amyloid plaques are formed by extracellular Aβ42 and the NFTs 
in neurons are formed by P-tau protein.The disease progression is closely linked to 
progression of neurofibrillary formations throughout the brain (42).  
 
At autopsy, when both plaques and tangles are seen in the entorhinal cortex and 
hippocampus, the diagnosis is confirmed as AD. Neuronal loss is a prominent factor 
caused by tangle overload intracellularly in the temporal neocortex and hippocampus. 
The death of neurons leads to increasing volume loss in the MTL, detectable by CT and 
MRI, and a hypoperfusion in the region, detectable by SPECT and PET. 
 
Medial temporal lobe atrophy is suggested to be a diagnostic marker for AD (45).One 





The development of the hippocampus has been explained as a progressive infolding of 
the foetal gyrus dentatus, cornu ammonis, subiculum and parahippocampal gyrus 
around the progressively smaller hippocampus sulcus (46). By the 21st
 
 week of 
gestation the hippocampus and surrounding structures appear similar as in the adult 
brain (47). The fully inverted hippocampus has an oval configuration in coronal MR 
images. Incomplete hippocampal inversion is found in 19% of the population and in 
these cases the hippocampus retains a round or pyramidal shape on the affected side. 
Unilateral hippocampus malrotations are seen in 13% of individuals and only on the 
left side. Bilateral, incomplete inversion is seen in 6% (47) of the population. The 
hippocampus on the right side is normally somewhat larger than on the left side and 
females on average have a larger hippocampus, normalized to intracranial volume 
(ICV), than males (39). 
The hippocampus together with the cingulate cortex, olfactory cortex and amygdala is 
part of the limbic system. The hippocampus plays an important role in the consolidation 
of information from short-term memory to long-term memory and also in spatial 
navigation.  
 
Damages to the hippocampus may affect it unilaterally or bilaterally and may be caused 
by infarction, tumour, encephalitis or MTL epilepsy, among other causes. Patients with 
unilateral hippocampal damage leaving the structure intact on the contralateral side, can 
retain nearly normal memory function (48). Bilateral damage to the hippocampus 
results in profound difficulties in forming new memories and also affects memory 
formed before the damage. The most famous patient without hippocampus function 
was Henry Gustav Molaison. Both his hippocampus formations were surgically 
removed in an attempt to relieve his epileptic seizures (49). After surgery he was 
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unable to form new episodic memories. Also he could not remember what happened 
shortly before the operation, but was able to retain some memories from his childhood 
(50).In early AD, episodic memory impairment is one of the first symptoms and it is 
also the core symptom in new research criteria for AD (51). 
 
1.5.2.1 Hippocampus in normal ageing 
For many years it was an accepted fact that neurons were irreplaceable. Neurons did 
not regenerate. They lived and they died. In 1998 Eriksson et al published a paper on 
neurogenesis in the human brain (52). They showed that new neurons are formed in the 
hippocampus in the adult human brain. This new nerve cell formation is found in the 
subgranular zone in dentate gyrus in the hippocampus. Later, neurogenesis was shown 
to also take place in the subventricular zone and the olfactory bulb (53) and in a more 
pronounced way than in the hippocampus (53).There is a normal volume loss in the 
hippocampus with age. After about 70 years of age there is a significant difference in 
the linear atrophy slope progression. This age was therefore suggested to be the starting 
point of an acceleration of atrophy in the hippocampus (39).  
 
1.5.2.2 Hippocampus in Alzheimer’s disease 
Alzheimer’s disease starts in the entorhinal cortex and from there expands to the 
hippocampus.The neuron loss in the hippocampus in AD is located to the subiculum 
and dentate granular layer (54). Note that new nerve cells are formed just beneath, in 
the hippocampal subgranular layer in the dentate gyrus (52).  
 
Hippocampal atrophy is a common feature in advanced AD. This atrophy is easily 
detected by both CT and MRI (11, 14, 45). Autopsy studies have reported 36–60% 
reduction in hippocampal volume in late AD compared with normal ageing (55). 
Volumetric measurements of the hippocampus and visual assessment of MTA atrophy 
based on MRI sequences are used in the work-up and diagnosis of MCI and AD (45). 
Subjects with MCI have a higher risk to progress to AD (56-59) but a substantial 
proportion remains stable or revert back to normal. 
 
In early-onset AD, atrophy may first be noticed in the precuneus region while the 
hippocampus may stay unaffected even late in the disease process (60). Hippocampus 
atrophy is, furthermore, not specific to AD (61) and can be present also in other 
cognitive disorders. In frontal lobe dementia (FLD), for example, hippocampus atrophy 
and frontotemporal atrophy may be strongly marked. Hippocampus atrophy can also be 
pronounced in vascular dementia (VaD), dementia of Lewy body type (DLB) and 
semantic dementia and in mixed forms (SD) (62, 63) but it can also be a normal finding 
in the very old (39).  
 
1.5.3 Evaluating brain atrophy 
1.5.3.1 Autopsy 
Senium means old age. Already in the 7th
 
 century B.C., Pythagoras divided life into five 
distinct stages at the ages of 1–7, 8–21, 22–49, 50–63 and 64–81 years. The two oldest 
groups were described as “a period of decline and decay of human body and regression 
of mental capacities” (64, 65).  
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Roger Bacon in the 13th
 
 century was probably the first to refer to the brain as a source 
of memory and thoughts. He thought the ventricular system in the brain consisted of 
three ventricles, the anterior ventricle for the imagination, the middle one for thought 
and judgment and the posterior ventricle for memory (64, 66).  
Dissection of the human body has in different ways been performed for thousands of 
years, at the beginning for mummifying purposes only, but later on with an interest in 
learning human anatomy and pathology. In the 17th
 
 century when dissections of the 
human body for anatomical study became less taboo there was an increasing trend 
towards researching underlying organic changes in the brain as the source of mental 
disorders (66). In 1864 Wilks (64, 67) described decrease in brain weight as a sign of 
atrophy. He also described brain atrophy, saying that “instead of sulci meeting, they are 
widely separated and their intervals are filled with serum … and the full depth of the 
sulci can be seen” (64, 67). 
It may have been Galileo Galilei who invented the microscope in 1609, but it was only 
after improvements in microscopy, in the late 19th
 
 century, and with new histochemical 
techniques, that we could properly look at parts of the nervous system for the first time. 
In 1898 Redlich described two cases of senile dementia with miliary sclerosis (64, 68), 
and in 1907 using the new Bielschowsky stain, Alzheimer described the findings in the 
first recorded early-onset AD case (1, 2). Today’s techniques of performing a brain 
autopsy and staining are improved since 1907, but are built on the same principles as 
Alzheimer’s technique. 
Macroscopically the AD brain at autopsy shows widening of the ventricles and sulci, 
cortical thinning and MTA. Brain weight loss is more pronounced in younger than in 
older AD patients (69). 
 
A problem today is that the overall autopsy rate is decreasing and continues to decline 
in the Western countries (70). For this reason, brain banks for brain donations and to 
ensure research possibilities are being formed all over the world. The Brain Bank of 
Karolinska Institute was started in 1972 thanks to the pioneering work of Prof. Bengt 
Winblad. The bank now can provide brain tissue for research on neurological diseases, 
for experimental purposes and for education (71). 
 
1.5.3.2 Visual assessment 
Visual assessment of brain changes, on MRI or CT images, is what neuroradiologists 
perform every day, often resulting in different assessments for different radiologists 
depending on skill and experience. In an attempt to standardize the visual assessments 
in clinical studies, among others the Fazekas group and Wahlund team have created 
grading scales for white matter changes (WMCs). Scheltens’ group in Amsterdam have 
devised grading scales for global cortical atrophy (GCA), visual assessment of MTA 
(vaMTA) and, recently, a grading scale for visual assessment of posterior atrophy (PA). 
A new multi-functional rating scale, the Brain Atrophy and Lesion Index (BALI); was 




The GCA scale gives the mean score for cortical atrophy throughout the entire 
cerebrum and is based on a study by Pasquier et al (73) in 1996. The visual assessment 
of GCA is based on consideration of the width of the sulci and the volume of the gyri in 
all lobes of the cerebrum and can also be used for the cerebellum. It is a 4-point scale, 
where 0 = no cortical atrophy; 1 = mild atrophy, and opening of the sulci; 2 = moderate 
atrophy, with volume loss of the gyri; and 3 = severe atrophy, also known as end-stage, 
“knife-blade” atrophy. In the initial study, dilatation of the ventricles was also staged 
(73). The cortical atrophy can be general, focal and/or asymmetric and it can be a 
pathological sign or a normal finding in the very old.  
Global cortical atrophy 
 
With repeated MRI investigations and documentation of increasing cortical atrophy and 
ventricular enlargement, GCA staging is a valuable tool for diagnosis of AD (74, 75). 
Assessment of focal cortical atrophy may identify patients with FLD, SD, primary 
progressive aphasia and posterior cortical atrophy (74). 
 
1.5.3.2.2 
Alzheimer’s disease is typically associated with MTA, but MTA can also be present in 
other forms of dementia such as FTD, VaD, DLB and can be seen in normal ageing.  
In early-onset AD or in individuals with prominent visual problems due to AD, atrophy 
can be seen in the posterior cingulate gyrus, precuneus and parietal lobes. Sometimes 
this atrophy is seen without any sign of MTA (60, 76, 77).  
Posterior atrophy 
 
Visual assessment of posterior cortical atrophy, on MRI, has been described in a newly 
published paper by Koedam et al (77). A visual rating scale for PA has been developed, 
consisting of an assessment in three dimensions, sagittal, coronal and axial. It is a 4-
point scale, where 0 = no atrophy; 1 = mild widening of the sulci without evident 
volume loss of the gyri; 2 = substantial widening of the sulci and volume loss of the 
gyri; 3 = severe end-stage atrophy. The anatomical structures that are evaluated in three 
dimensions are the posterior cingulate sulcus, parieto-occipital sulcus, precuneus and 
parietal lobe.  
 
This study showed that visual assessment of PA was able to discriminate individuals 
with AD from other dementias and controls, while vaMTA failed to discriminate AD 
from other dementias. This suggests that a combination of vaMTA and visual 
assessment of PA may increase the sensitivity for AD (77). 
 
1.5.3.2.3 
Visual assessment of MTA was developed in the early 1990s by Philip Scheltens’ team 
in Amsterdam. The first publication was a validation of visually assessed atrophy using 
linear measurements of the MTL (78). The assessment was revised in 1995 (79) and 
apart from some small adjustments the method for visual assessment has remained 
unchanged since then. There are other methods for assessment of MTA, but most of 
them are further developments of Scheltens’ original method (59, 80). 
Medial temporal lobe atrophy 
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The vaMTA is based on a 5-point grading scale. The assessment is performed on a 
coronal MRI image which can be angulated perpendicular to the anterior-posterior 
commissure (AC-PC) line or perpendicular to the long axis of the hippocampus, which 
is a coronal line along the brainstem axis (59, 79, 81). Structures evaluated are the 
choroid fissure, the temporal horn of the lateral ventricle and the hippocampus 
formation including the hippocampus proper, subiculum, parahippocampal gyrus and 
dentate gyrus.  
 
The MTA scores range from 0 = no atrophy; to 1 = slightly increased width of the 
choroid fissure; 2 = increasing width of the choroid fissure, slightly increased width of 
the temporal horn and slightly decreasing height of hippocampus; 3 = wide open 
choroid fissure, increasing width of the temporal horn and progressive decrease in 
hippocampal height; and 4 = end-stage atrophy with wide open choroid fissure and 
temporal horns and a minimal hippocampus (79). 
 
With the new, multi-detector CT technique it is possible to achieve good-quality CT 
images in any desired plane for vaMTA. A comparison between 64-detector row CT 
and 1.5 Tesla (T) MRI performed by Wattjes et al (11) showed good agreement 
between CT and MRI. The correlation between hippocampal volume and MTA has 
been shown to be statistically significant, but the correlation coefficient is low (81). 
Perhaps MTA is more likely to reflect whole brain atrophy compared with just 
hippocampal atrophy. In a work by Knoops et al this has been suggested (82). 
 
1.5.3.3 Linear measurements 
Even before the CT and MRI era, linear measurements were performed on plain films. 
An indirect measurement of atrophy was the Evans ratio. This involves dividing, using 
a pneumoencephalogram, the maximal anterior width of the lateral ventricles by the 
maximal intracranial width in an anterior-posterior plain film view (83).  
 
Linear measurements have also been used in CT to evaluate brain atrophy (84, 85). The 
measurements were used to calculate ratios between structures in order to compare 
controls with diseased individuals. The dilatation of the lateral and third ventricles was 
thought to be an effect of central atrophy. In longitudinal studies increasing distances or 
decreasing ratios were noted for AD patients compared with controls (86). 
 
In a recent study by Zhang et al (87) linear measurements on CT images were 
investigated in a population of AD patients and healthy elderly. Only two ratios of 
significance were found, the temporal horn ratio and the suprasellar cistern ratio. An 
increase in the temporal horn ratio reflects the enlargement of ventricles caused by 
MTA. Also, the suprasellar cistern ratio increases with increasing MTA (87).Linear 
measurements in MRI investigations of atrophy are not often seen, but a few studies 
have reported significant results when comparing linear measurements in individuals 
with AD or MCI, and controls (78, 88). 
 
1.5.3.4 Volumetry 
In volumetry, a structure or a cavity can be outlined and calculated, discovering even 
very small differences in or between individuals in longitudinal studies (89). Volumetry 
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is mostly used in MRI, but before the MRI era, CT volumetry was used, especially in 
calculating ventricular volumes (86).  
 
Volumetry using MRI can be performed on all regions that have well-defined borders. 
For example, in the diagnosis of AD hippocampus, amygdala and entorhinal cortex, 
whole-brain volume or cortical thickness can be outlined and calculated. All these 
regions are of interest in the work-up of AD, but volumetry is time-consuming and so 
far has been used only in research.  
 
Manual outlining of the hippocampus, amygdala and entorhinal cortex is often 
performed on a three-dimensional (3D) T1-weighted MRI sequence (39). The 
structures may be outlined in the coronal projection (39) or in a sagittal projection (90) 
but all three image planes, sagittal, coronal and axial orientations, are used to control 
the delineations.  
 
The programs used for manual volumetric calculation differ, as do the techniques to 
outline the structures. Besides the manual outlining, semi-automatic and automatic 
methods can be used. The variety of software programs available for semi-automatic 
and automatic segmentation techniques (90, 91) is large. 
 
Manual outlining is highly dependent on the investigator. A manual segmentation of 
hippocampus volume, performed by a skilled investigator, is better than other 
techniques such as vaMTA or automatic calculation of hippocampal volume (91) in 
detecting atrophy. 
 
An important advantage in using automatic segmentation rather than manual 
assessment is the consistency and reproducibility of the segmentations, which almost 
completely eliminates investigator bias (90). 
 
 
1.6 NEW PROPOSED CRITERIA FOR ALZHEIMER’S DISEASE 
The clinical criteria for AD were outlined in 1984 by the NINCDS-ADRDA (8). These 
criteria are based on a two-step work-up. Firstly the diagnosis of dementia has to be 
made. Secondly the aetiology of the dementia disorder is established based on distinct 
observations of symptoms and clinical signs.  
 
Since 1984 the general use of CT, MRI, PET, biomarkers in CSF, and genetics has 
made it possible to diagnose AD much earlier in the disease process than was 
previously possible and in some cases even before any symptoms have appeared. This 
has raised the need for new, updated criteria for AD diagnosis in order to bring the time 
point of the diagnosis forward to precede the development of the dementia syndrome 
where the diseased person is no longer in charge of themselves.  
 
The first step in this direction came in 2007 with a publication by Dubois et al (51). In 
this paper new research criteria for AD were based on a core criterion and supportive 
biomarkers. Early and significant episodic memory impairment is the core criterion. 
Supportive features to the core criterion are presence of MTA, abnormal CSF markers, 
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specific patterns on functional neuroimages with PET, and proved AD autosomal 
dominant mutation within the immediate family. According to these research criteria, 
the core criterion and one of the supportive factors are enough for diagnosing “probable 
AD” (51). 
 
In 2009 the National Institute on Aging (NIA) and the Alzheimer’s Association 
sponsored a series of round table meetings whose purpose was to establish a process for 




















Fig. 1. Model of the clinical trajectory of Alzheimer’s disease (AD). The stage of preclinical 
AD precedes mild cognitive impairment (MCI) and encompasses the spectrum of presympto-
matic autosomal dominant mutation carriers, asymptomatic biomarker-positive older 
individuals at risk for progression to MCI due to AD and AD dementia, as well as biomarker-
positive individuals who have demonstrated subtle decline from their own baseline that 
exceeds that expected in typical aging, but would not yet meet criteria for MCI. Note that this 
diagram represents a hypothetical model for the pathological-clinical continuum of AD but 
does not imply that all individuals with biomarker evidence of AD-pathophysiological process 
will progress to the clinical phases of the illness. Figure and figure text from Sperling R et al 
2011 (92). 
 
The recommendation from these advisory meetings was to form three separate 
workgroups, each with an assigned task to formulate diagnostic criteria for the 
asymptomatic preclinical phase of AD, the symptomatic preclinical phase of AD and 
the dementia phase of AD, respectively. A fourth separate group was later tasked with 
revising neuropathological criteria for AD (93). The recommendations from the initial 
three workgroups were presented in a symposium at the 2010 International Conference 
in Alzheimer’s Disease (ICAD) meeting in Honolulu, Hawaii. The documents were 
revised and all three documents were submitted simultaneously in 2011. The 
recommendation from the neuropathology workgroup was supposed to be in late 2011 
(93).  
 
A general problem for the members in the workgroups has been to define specific cut-
off points for normal versus abnormal values for neuroimaging and CSF biomarkers. 
Regarding CSF biomarkers, work needs to be done with regard to uniform assessment, 
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standardization and use of the laboratory techniques to evaluate the biomarkers Aβ,  
T-tau and P-tau (93). 
 
In 2010 Jack et al published a hypothetical model of dynamic biomarkers of 
Alzheimer’s pathological cascade (94). This cascade shows the dynamics of the 
biomarkers’ relation during stages of cognitively normal individuals in the preclinical 
stage, through MCI to dementia (Fig. 2). In his hypothetical model of the disease 
cascade there may be abnormal accumulation of Aβ, detectable with PET-PIB first in 
the frontal lobes, 10–20 years before symptoms become noticeable. Brain Aβ 
accumulation is necessary but not sufficient to produce clinical symptoms (92). 
Cognitive symptoms are directly related to neurodegeneration and increasing T-tau and 
P-tau and these may be pathological in the late preclinical stage or early MCI. Magnetic 
resonance imaging or volumetry of MTL structures may turn pathologic inthe MCI 
stage parallel to the cognitive reduction debut, but only in the dementia stage does 
clinical function drop (94). None of the biomarkers is static; they change over time and 
follow a non-linear time course which is hypothesized to be sigmoidal in shape. 
 
This diagram makes it easier to understand the disease development in AD, but note 
that this a hypothetical model (Fig. 2). 
  



















Fig. 2. Hypothetical model of dynamic biomarkers of the AD expanded to explicate the 
preclinical phase: Ab as identified by cerebrospinal fluid Ab42 assay or PET amyloid imaging. 
Synaptic dysfunction evidenced by fluorodeoxyglucose (F18) positron emission tomography 
(FDG-PET) or functional magnetic resonance imaging (fMRI), with a dashed line to indicate 
that synaptic dysfunction may be detectable in carriers of the ε4 allele of the apolipoprotein E 
gene before detectable Ab deposition. Neuronal injury is evidenced by cerebrospinal fluid tau 
or phospho-tau, brain structure is evidenced by structural magnetic resonance imaging. 
Biomarkers change from normal to maximally abnormal (y-axis) as a function of disease 
stage (x-axis). The temporal trajectory of two keyindicators used to stage the disease 
clinically, cognitive and behavioral measures, and clinical function are also illustrated.  
Figure and figure text are slightly modified by Sperling R et al (92) but orginates from Jack 
CR et al, (93).   
The results of the three workgroups were formulated into diagnostic criteria for three 
stages of AD: the asymptomatic preclinical phase of AD, the symptomatic preclinical 
phase of AD, and the dementia phase of AD. The first stage, the asymptomatic 
preclinical phase of AD, is subdivided into three phases, according to the preclinical 
workgroup (94).These three phases in the first stage are for preclinical research use 
only and are built on absence or presence of Aβ, markers of neuronal injury and 
evidence of subtle cognitive change. 
 
The second stage, the symptomatic predementia phase of AD, has also been named 
“mild cognitive impairment due to AD” by Albert et al (95). For a patient to be referred 
to as second stage AD, the core criteria for MCI, listed below, must be met first. 
 
The core criteria for the diagnosis of MCI are: 
1. Concern regarding a change in cognition 
2. Impairment in one or more cognitive domains 
3. Preservation of independence in functional abilities 
4. Not demented 
 
In the third stage, the dementia or “dementia due to AD” stage (96), the core criteria for 





The core criteria for dementia are: 
1. Interference with the ability to function at work or at usual activities 
2. Decline from previous levels of functioning and performing 
3. Condition not caused by delirium or major psychiatric disorder 
4. Cognitive impairment 
5. Cognitive or behavioural impairment in at least two of following domains: 
 a. impaired ability to acquire and remember information 
 b. impaired reasoning and handling of complex tasks 
 c. impaired visuospatial functions 
 d. impaired language functions 
 e. changes in personality 
 
In this stage there are seven different phases more or less confirming the diagnosis of 
“dementia due to AD”, according to McKhann et al (96). As with the second stage, 
additive features are absence or presence of biomarker of AD type, Aβ, and neuronal 
injury, together with fulfilled core criteria of AD. 
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2 AIMS OF THE THESIS 
The overall purpose of this thesis was to test the reliability of vaMTA in different 
settings. This was done in four studies with specific aims as follows: 
 
StudyI To investigate intra- and inter- rater agreement of visual assessment of 
MTA over a period of one year. 
 
Study II To evaluate visual assessment of MTA compared with hippocampus 
volume in an elderly non-demented population. A second aim was to 
create cut-off normal MTA score values for different age groups for use 
in a clinical evaluation. 
 
Study III The first aim was to compare the performance of the multivariate 
technique, orthogonal projections to latent structures (OPLS), with visual 
assessment of MTAand hippocampal volume to differentiate between AD 
cases and controls. The second aim was to assess how well the three 
different approaches predicted conversion from MCI, at baseline, to AD 
at one year follow-up.  
 
Study IV To validate the proposed new research criteria for AD, from 2007, in a 
naturalistic sample of patients with memory disturbances. The second aim 
was to assess the concordance between the proposed new research criteria 
and the clinical evaluation according to the traditional disease 
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3 MATERIALS AND METHODS 
Three of the studies, studies I, II and IV, were approved by the ethical committee at 
Karolinska Institutet. The Norwegian part of study I was approved in a letter of 
notification from Professor Knut Engedal at Hukommelsesklinikken, Ulleval 
University Hospital, Oslo, Norway. Study III was approved by the ethical review 
boards in each of the participating countries (the United Kingdom (UK), Finland, 
France, Greece, Italy and Poland) verified by a letter of notification from Professor 
Simon Lovestone at the MRC Centre for Neurodegeneration Research, King’s College 
London, UK.  
 
3.1 PATIENTS 
Study I: In this retrospective study, 100 out-clinic patients with memory problems 
were included, 50 from Minnesmottagningen, Karolinska University Hospital, 
Huddinge, Stockholm, Sweden, and 50 from Hukommelsesklinikken, Oslo University 
Hospital, Ulleval, Oslo, Norway. All patients underwent an MRI protocol for geriatric 
patients, according to local clinical standards. A clinical report was written before 
including patients in the study.  
 
The Swedish population were examined during 2001–2004 and the Norwegian 
population between 2006 and 2008. Patients in the Swedish group were younger (44–
69, mean 59, years) compared with those in the Norwegian group (52–87, mean 78, 
years). The inclusion criterion was a good-quality MRI with a coronal T1 sequence 
covering the hippocampus head and neck and at least parts of the hippocampal body. 
Patients were selected to represent all grades of MTA. 
 
Study II: In this comparative study, 555 subjects, a sub-sample of an epidemiological 
study of 3,363 healthy, non-demented elderly individuals ( ≥60 years of age), were 
included in the Swedish National Study of Ageing and Care in Kungsholmen  
(SNAC-K). This is a longitudinal, multidisciplinary study on ageing and health, which 
began in 2001. The SNAC-K was created to detect the influence of lifetime genetic, 
environmental and biological factors on medical, psychological and social health in late 
adulthood. The SNAC-K samples were stratified for age and year of assessment. Ten 
age cohorts were chosen, with different assessment intervals: 6-year intervals in the 
younger cohorts (60–78 years old), and 3-year intervals in the older cohorts (aged ≥  
81). The MRI examinations were performed during 2001–2003. Subjects with severe 
cerebral diseases that directly affect brain atrophy were excluded.  
 
On average, the selected 555 subjects were slightly younger, more educated, and 
cognitively advantaged compared with the remaining sample. After a quality 
assessment of the baseline MRI images, 544 subjects (60–97 years old), 318 females 
and 226 males, were finally included in the MRI study of volumetric measurements 
while all 555 (320 females and 235 males) were included in the visual assessment 
study. When comparing the two studies the same 544 subjects were used. Because of 
the limited sample size in the age groups ≥87 years, we categorized all participants 
aged 87 and older as one group. In total, we therefore investigated seven age groups: 
60, 66, 72, 78, 81, 84 and ≥87 year olds. 
 20 
Study III: All patients in this study were enrolled in the AddNeuroMed project, part 
of Innovative Medicines in Europe (InnoMed), a European Union (EU) programme 
designed to make drug discovery more efficient. Data were collected from six 
different sites across Europe: the University of Kuopio, Finland; the University of 
Perugia, Italy; Aristotle University of Thessaloniki, Greece; King’s College London, 
in the UK; the University of Lodz, Poland; and the University of Toulouse, France. 
Magnetic resonance imaging images from *257 subjects were included in this study, 
75 AD patients, 101 MCI patients and 81 healthy controls. 
 
All AD and MCI subjects were recruited from local memory clinics of the six 
participating sites while the control subjects were recruited from non-blood-related 
members of the patients’ families, caregivers’ relatives or from social centres for the 
elderly. The inclusion criteria for AD were: NINCDS-ADRDA and DSM-IV criteria 
for probable AD, Mini Mental State Examination (MMSE) score range between 12 
and 28, Clinical Dementia Rating (CDR) score ≥0.5, and ≥65 years  old. The inclusion 
criteria for MCI were: MMSE score range between 24 and 30, Geriatric Depression 
Scale (GDS) score ≤5, CDR = 0.5, and age ≥65 years. The distinction between MCI 
and controls was in CDR scores. Controls rated 0 and MCI patients scored 0.5. 
Exclusion criteria were significant neurological or psychiatric illness other than AD, 
VaD or large infarcts. Patients with significant unstable systematic illness or organ 
failure were likewise excluded. 
*A misestimation in the published paper III stated 252 subjects 
 
Study IV: From a total of 600 patient files with consecutive new referrals to 
Minnesmottagningen, Karolinska University Hospital, Huddinge, during the years 
2001–2006, 150 patients had performed additional work-up according to the new 
criteria set by Dubois et al (51). These 150 subjects were included in this 
retrospective study. The mean MMSE score was 26 (range 18–30), mean age 59 
(range 41–78) years, and mean CDR 0.5. The inclusion criteria in the study were an 
objective history of episodic memory dysfunction, CSF analyses, SPECT and/or 
vaMTA. None of the patients had undergone all the procedures available in the work-
up of dementia. According to the cerebral MRI and/or CT scan, patients with 
intracerebral tumours, normal pressure hydrocephalus and cortical strokes were 
excluded. As our sample were retrospectively drawn from the routine clinical records 
and did not represent a preselected research cohort, they were a true naturalistic 





3.2.1 Magnetic resonance imaging 
Study I: Magnetic resonance imaging was performed at the Department of Radiology 
at Karolinska University Hospital, Huddinge, Sweden, using one of their three 1.5 T 
MRI scanners: Siemens Vision, Symfoni or Avanto (all from Siemens, Erlangen, 
Germany). A T1-weighted 3D magnetization-prepared, rapid-gradient echo sequence 
(MPRAGE), time of repetition (TR) 11.4 ms, time echo (TE) 4.4 ms and flip angle 10, 
was used to grade MTA. The coronal plane was selected perpendicular to a line 
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between the AC and PC in the midsagittal plane. This sequence yields 72 continuous 
coronal slices with a slice thickness of 2.5 mm, covering the whole brain. A good 
separation between grey and white matter was obtained. 
 
At the Curato Røntgeninstitutt in Oslo, Norway, two different MRI protocols were 
used, depending on the year of investigation. A Siemens Avanto 1.5 T MRI machine 
was used for all patients. For 13 patients investigated in 2006, the protocol included a 
coronal T1-weighted two-dimensional (2D) sequence with TR 450 ms, TE 9.4 ms and 
two acquisitions. The coronal sequence was angled perpendicular to the AC–PC line. 
The slice thickness was 4 mm, with a 0.4 mm gap between images. This sequence 
yielded 20 continuous slices. During the period 2007–2008 a coronal T1-weighted 3D 
time of flight (tfl) was used, with TR 1900 ms and TE 3.08. Slice thickness varied 
between 0.9 and 1 mm. The number of continuous slices varied between 41 and 110. 
The coronal orientation was perpendicular to the AC–PC line. This sequence was used 
for the remaining 37 patients from this centre. In both Norwegian protocols the head, 
neck and parts/whole body of hippocampus and MTL were covered and a good 
separation between grey and white matter was obtained.  
 
No corrections were made post-MRI to the images, regarding angulation in the coronal 
plane or sidewise asymmetry in the images. This means that the sequences included in 
this study were identical to the native sequences.  
 
Study II: The MRI scan was performed on a 1.5T scanner (Philips Intera, The 
Netherlands). In the SNAC-K project, 3D fast field echo (FFE) T1 MRI sequences 
were used. The 3D FFE T1 images (TR = 15 ms, TE = 7 ms, flip angle = 5°, number of 
slices = 128, thickness = 1.5 mm, field of view (FOV) = 240, matrix = 256*256) were 
used both for volumetric measurements of the hippocampus and ICV, and for vaMTA. 
The transversal images were reoriented to coronal sections perpendicular to the AC–PC 
line, according to the Talairach atlas (97) suitable for both volumetric and visual 
assessments. 
 
In a subgroup of 21 subjects, reorientation to coronal sections was performed both 
perpendicularly to the AC–PC line and parallel to the brainstem, in order to investigate 
whether there was any significant statistical difference when rating images with 
different angulation. 
 
Study III: Data acquisition for the AddNeuroMed study was designed to be 
compatible with the Alzheimer Disease Neuroimaging Initiative (ADNI) (98). The 
imaging protocol for both studies included a high resolution sagittal 3D T1-weighted 
MPRAGE volume (voxel size1.1x1.1x1.2 mm³). The MPRAGE volume was acquired 
using a custom pulse sequence specifically designed for the ADNI study to ensure 
compatibility across scanners (98). Full brain and skull coverage was required and 
detailed quality control was carried out on all MR images according to the 





Study IV: A standardized protocol for geriatric purposes was used, performed on a 
1.5 T Siemens Vision (Symfoni and Avanto) scanner (Siemens, Erlangen, Germany). 
Visual assessments were based on a T1-weighted 3D MPRAGE sequence, TR = 11.4 
ms, TE = 4.4 ms and flip angle = 10. The coronal plane was chosen, perpendicular to 
a line between the AC and PC in the midsagittal plane. This sequence yields 72 
continuous coronal slices, with a slice thickness of 2.5 mm, covering the whole brain. 
A good separation between grey and white matter was obtained. 
 
3.2.1.1 Visual assessment of the medial temporal lobe 
Studies I-IV: The MTL was bilaterally visually assessed regarding atrophy on coronal 
MRI images. The MTA scale was invented by Philip Scheltens et al(published in 1992 
(78) for the first time) for use on plain films. Later the technique was modified (79) for 
use with digital images. Visual assessment of MTA was performed on one specific 
coronal MRI slice, behind the amygdala and mamillary bodies, in the position of the 
cerebral peduncles. It was based on a visual estimation of the MTL volume. The visual 
assessment included the hippocampus proper, dentate gyrus, subiculum, 
parahippocampal gyrus, entorhinal cortexand surrounding CSF spaces such as the 
temporal horn and choroid fissure (Table 1). The right and left side were rated 
separately. Scores ranged from 0 to 4 (Fig. 3), with 0 = no atrophy; 1 = slightly 
increased width of the choroid fissure; 2 = increasing width of the choroid fissure, 
slightly increased width of the temporal horn and slightly decreasing hippocampal 
height; 3 = wide open choroid fissure, increasing width of the temporal horn and 
progressive decrease of hippocampal height; and 4 = end-stage atrophy with wide open 
choroid fissure and temporal horns and a small hippocampal volume (79). 
 
Table 1. Visual assessment of medial temporal lobe atrophy (vaMTA), using the scale by Philip 
Scheltens et al (78, 79) Copyright © 1992, British Medical Journals (with permission). 
 
















































N normal,↑increasing, ↓decreasing. Atrophy increases with an increased score-number.  
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Fig. 3. Visual assessment of medial temporal lobe atrophy (vaMTA). The images show, from 
left to right, MTA scores 0–4. 
 
3.2.1.2 Volumetric measurements 
Studies II and III: Magnetic resonance images were transferred to a HERMES 
workstation (Nuclear Diagnostics, Stockholm, Sweden). The transversal 3D T1 FFE 
images were reoriented to coronal sections perpendicular to the AC–PC line, according 
to the Talairach atlas (97). STEREOLOGY (100), volumetric software in HERMES, 
was used to obtain ICV. This is a semi-automatic method for estimating large brain 
structures which it is time-consuming to delineate. Intracranial volume was used to 
adjust the hippocampal volume to different head sizes. With a region of interest (ROI) 
tool in HERMES Multi Modality, hippocampal formation was manually delineated and 
the hippocampal volume was calculated. The volumetric method and volumetric work 
in these two studies has been described in detail in a previous publication by Zhang et 
al from 2010 (39). 
 
3.2.1.3 Regional volume segmentation 
Study III: In this study Free-Surfer was used, a pipeline developed by Fischl and Dale 
(101) which produces measurements of regional cortical thickness and volumetric 
measures (Fig. 4). Cortical reconstruction and volumetric segmentation includes 
removal of non-brain tissue using a hybrid watershed/surface deformation procedure 
(102), automated Talairach transformation, segmentation of the subcortical white 
matter and deep grey matter volumetric structures (including hippocampus, 
amygdala, caudate, putamen, ventricles) (102–104), intensity normalization (105), 
tessellation of the grey matter white matter boundary, automated topology correction 
(106, 107), and surface deformation following intensity gradients to optimally place 
the grey/white and grey/CSF borders at the location where the greatest shift in 
intensity defines the transition to the other tissue class (101, 108, 109). Once 
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thecortical models are complete, registration to a spherical atlas takes place which 
utilizes individual cortical folding patterns to match cortical geometry across subjects 
(110). This is followed by parcellation of the cerebral cortex into units based on gyral 
and sulcal structure (111, 112). The left and right side of volumes and thicknesses 
were averaged. The regional cortical thickness measures were originated from 34 
areas and the regional volumes were measured from 23 areas. All volumetric 
measures from each subject were normalized to the subject’s ICV. Thickness 























Fig. 4a and b. Representations of ROIs included as candidate input variables in the 
multivariate OPLS model. (A) Regional volumes. (B) Regional cortical thickness measures. 




Study IV: The cerebral metabolism reflected by cerebral blood flow (CBF) was 
examined by SPECT using a visual assessment combined with a semi-quantitative 
method, with the Brain Registration Analysis and Software suite (BRASS) (113). 
After injection of 1000 MBq Tc-99m-HMPAO in quiet surroundings with the 
patient’s eyes closed, SPECT perfusion was performed according to standard clinical 
procedure. Acquisition was started 30 minutes after injection. Data were collected in 
60 projections evenly spread through 360° with a triple-headed rotating gamma 
camera (Picker IRIX, Cleveland, OH, USA) and a total acquisition time of 22 
minutes. Tomographic slices were reconstructed using an iterative algorithm (Hosem, 
Nuclear Diagnostics AB, Stockholm, Sweden) with Chang attenuation correction 
(attenuation coefficient: 0.12/cm). Data were formatted as a 3D dataset with 128 x 
128 x 64 voxel (64 transversal sections) and a voxel size of 1.75 x 1.75 x 3.5 mm³. 
The reconstructed datasets were post-filtered with a Butterworth filter (cut-off 
1.0/cm). The resolution in a tomographic slice was measured at 10.2 mm full width at 
half maximum. 
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3.2.3 Cerebrospinal fluid analysis 
Study IV: Cerebrospinal fluid was obtained by standard procedure lumbar puncture 
in all patients agreeing to undergo this procedure. All samples were stored at –80°C 
until analysis. Cerebrospinal T-tau, Aβ 42 and P-tau were determined using a 
sandwich enzyme-linked immunosorbent assay (ELISA) constructed to measure these 
proteins (114). Two internal CSF pools were run on each ELISA to assure its 
reproducibility (115). The reference values (Aβ42 <427 ng/l, T-tau >445 ng/l or P-tau 
>74 ng/l) published by Wallin et al (114) were used as cut-off values. 
 
 
3.2.4 Clinical assessments 
Study IV: Since the core feature in the suggested new criteria by Dubois et al (51) is 
persistent reduction in episodic memory function, we included only patients who had 
been examined based on the RAVLT (116). This is a list of 15 words presented to the 
patient five times, reflecting episodic memory capacity (immediate and delayed 
recall). The cut-off for the pathological delayed recall test was set at <6 (out of the 
total of 15 words), according to previous findings (117). Global cognitive function 
was assessed using the MMSE (118), performed according to standard procedure by 
the routine clinical physicians seeing the patients at the first consultation at the 
memory clinic. Memory function including the RAVLT was assessed by a trained 
neuropsychologist. A grading of the cognitive impairment using CDR (119) was 
performed by a senior consultant when the patients were discussed in the diagnostic 
consensus meeting. The diagnosis was made according to the consensus criteria for 
MCI by Winblad et al. (120) , the ICD-10/DSM-IV criteria for dementia (3, 4), the 
NINCDS-ADRDA for AD (8), the NINCDS-AIREN for VaD (121) and the 
Manchester criteria for FTD (115). For the diagnosis of subjective cognitive 
impairment (SCI), we used the ICD-10 classification of “Z03.3 = observation for 
possible neuro-organic disorder” (3) when the patient had subjective memory 
problems that could not be objectively confirmed. When the dementia diagnosis was 
unclear, the ICD-10 classification for unspecified dementia (dementia UNS) was used 
(3). 
 
3.2.5 Statistical analysis 
 
Study I: Intra- and inter-rater reliability was performed with kappa and weighted kappa 
statistics (122, 123). The extent of the agreement between the repeated assessments 
from the radiologists concerning each patient is the proportion between the number of 
pairs for which there was agreement, and the total numbers of possible pairs of 
assignments. These values were calculated and stored in a data file. In order to compare 
the two raters and the two sites with respect to a patient’s “agreement score”  
a generalized estimating equations (GEE) model was performed using the GENMOD 
procedure in SAS(SAS Institute Inc., Cary, NC, USA) (124). The GEE strategy is a 
useful approach for repeated measurement analysis of ordered categorical outcomes.  




Study II: Multivariate analysis of variance (MANOVA) was used to compare the 
differences in brain structure volumes between women and men, adjusted for age and 
ICV. Dependent t-tests were performed to identify the difference in hippocampal 
volume between the right and left side (122).  
 
Spearman rank order correlation coefficient (rs) was used to measure the association 
between hippocampal volume and vaMTA, MTA score. Analyses were performed 
using Statistica version 9.0 (StatSoft®
 
, Inc., Tulsa, OK, USA). In comparisons between 
gender, age, and sides regarding MTA score, we used a GEE model and performed 
analyses using the GENMOD procedure in SAS, version 9.1 (SAS Institute Inc., Cary, 
NC, USA). The GEE strategy is a useful approach for repeated measurements analysis 
of ordered categorical outcomes. The model was set up for the within-group factor side 
(Sin, Dx) and the between-groups factors gender (F, M) and age (seven categories). 
Intra-rater reliability was analysed using kappa and weighted kappa for ordered 
categorical data, and intraclass correlation coefficient (ICC) for continuous data 
(volumetry). 
Study III: Magnetic resonance images were analysed using OPLS (125–127),  
a supervised multivariate data analysis method included in the software package 
SIMCA (Umetrics AB, Umeå, Sweden). A very similar method, Partial Least Squares 
(PLS) to latent structures, has previously been used in several studies to analyse MRI 
data (128, 129). The two methods OPLS and PLS give the same predictive accuracy, 
but the advantage of OPLS is that the model created to compare groups is rotated, 
which means that the information related to class separation is found in the first 
component of the model, the predictive component. The other orthogonal components 
in the model, if any, relate to variation in the data not connected to class separation. 
Focusing the information related to class separation on the first component makes 
data interpretation easier (127). 
 
Pre-processing was performed using mean centring and unit variance scaling. Mean 
centring improves the interpretability of the data, by subtracting the variable average 
from the data. By doing so the dataset is repositioned around the origin. Large 
variance variables are more likely to be expressed in modelling than low variance 
variables. Consequently, unit variance scaling was selected to scale the data 
appropriately. This scaling method calculates the standard deviation of each variable. 
The inverse standard deviation is used as a scaling weight for each MRI measure. 
Altogether 57 variables were used for OPLS analysis. No feature selection was 
performed, meaning all measured variables were included in the analysis. A model 
containing age was also created to test if there were any significant differences 
between the diagnostic groups in relation to this variable. 
 
Sensitivity and specificity were calculated from the cross-validated prediction values 
of the OPLS models and for the visual assessment. Finally, the positive and negative 
likelihood ratios (LR+ = sensitivity/100-specificity) and LR- = (100-sensitivity/-
specificity) were calculated. A positive likelihood ratio between 5 and 10 or a 
negative likelihood ratio between 0.1 and 0.2 increases the diagnostic value in a 
moderate way, while a value >10 or <0.1 significantly increases the diagnostic value 
of the test (130). 
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Finally the AD versus control (CTL) models were used as training sets to investigate 
how well they could predict conversion from MCI to AD after 1-year follow-up and 
how they compare to the visual assessment. To easily compare the performance of the 
three methods we also calculated the sensitivity (MCI converters predicted as AD) at 
a fixed specificity (MCI stable predicted as CTL). We set the specificity for all three 
methods for this comparison to that of the visual assessment since this cannot be 
changed, and recalculated the sensitivity and specificity for the other two methods. 
 
Study IV: Spearman rank order correlation coefficient was used to measure the 
association between the diagnosis of MCI and the biomarkers. The agreement 
between the diagnosis of MCI and the MRI, SPECT and RAVLT was analysed with 
κ- and weighted κ statistics. For the κ analyses, the variables were divided into three 
categories in the following way: diagnoses (0 + 1 = normal + SCI; 2 = MCI; and 3 = 
AD), MRI (0 + 1 = no atrophy; 2 = slight atrophy; and 3 + 4 = extensive atrophy), 
SPECT (0 = no pathology; 1 = slight pathology; and 2 = extensive pathology) and 
RAVLT delayed recall (3 + 4 = sum score 15-8, 2 = sum score 7–4 and 1 = sum 
scores 3–0). Judgments of correlation coefficients and κ values were made according 
to Landis and Koch (122) classifying the estimates as follows < 0.20 = poor, 0.21–
0.40 = fair, 0.41–0.60 = moderate, 0.61–0.80 = good and 0.81–1.00 = very good.  
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4 RESULTS 
Study I: Consensus ratings at time zero were compared with ratings at 1 week, 1 
month, 3 months, 6 months and 1 year and revealed variation between sides for both 
investigators. For the neuroradiologist, simple kappa ranged between 0.65 and 0.75 on 
the right side and between 0.66 and 0.72 on the left side. For the general radiologist, a 
decline was seen on the right side from 0.64 to 0.44, and on the left side from 0.61 to 
0.38 at the 3-month and 0.40 at the 1-year rating. Intra-rater weighted kappa showed 
almost perfect agreement (wκ 0.81–1.00) for both radiologists, with few variations over 
the year and little variation between the right and left side. The weighted kappa values 
varied between 0.88 and 0.92 on both sides for LC and between 0.86 and 0.89 on the 
right side and between 0.80 and 0.89 on the left side for KL (Fig. 5a and b). 
 
Inter-rater reliability was fair to moderate. The agreement between the two investi-
gators decreased during the year and dropped from κ 0.48 to κ 0.32 on the right side 
and from κ 0.48 to κ 0.28 on the left side. Weighted kappa values for inter-rater 
agreement showed little variation over the year, ranging from 0.79 to 0.84 on the right 
side and from 0.73 to 0.84 on the left side, with a dip at 1 month (κ 0.73), which 
corresponded to the simple kappa at 1 month (κ 0.28), on the left side (Fig. 6a and b).  
 
There was no statistically significant difference in MTA rating between the Swedish 
and Norwegian examinations (p=0.35), and there was no statistically significant 
interaction between country and investigator (p=0.57). There was no significant 
difference between the three T1-weighted sequences used for evaluating the MTL: 3D 
MP-RAGE, 3D tfl or coronal 2D T1. There was no difference in kappa when 
comparing thin (0.9–2.5 mm) with thick images (4 mm). A statistically significant 
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Fig. 5a and b. Agreement between consensus ratings at time zero and individual ratings over a 
period of 1 year, shown as kappa (K LC, K KL) and weighted kappa (wK LC, wK KL) for both 
investigators. Sin = left; Dx = right. 
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Fig. 6a and b. Left and right side inter-rater kappa (κ) and weighted kappa (wκ) values for the 
two investigators LC and KL. All the five ratings during the year from time zero are shown.  
Sin = left; Dx = right. 
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Study II: Sixty-five per cent or 362/555 of our study population of non-demented 
elderly were 60–72 years old and only 6% or 36/555 were ≥ 87 years of age. When we 
evaluated MTA score v. age we found a statistically significant difference between age 
cohorts (p<0.001). Pair-wise comparisons between cohorts revealed a significant 
difference between all groups, except between the two oldest age groups. The gender 
difference when using MTA score was statistically significant (p<0.001), showing a 
higher MTA score (i.e. more atrophy) for men than for women, but no statistically 
significant difference (p=0.25) in MTA score was found between the right and the left 
MTL.  
 
Among the non-demented elderly individuals included, there was a spread of MTA 
scores across the different age cohorts (Table 2). In the two youngest age groups (60 
and 66 years old) there was a predominance of MTA scores 0 and 1. Scores 0–2 were 
most prevalent in the age groups 72, 78 and 81 years, while in the two oldest age 
groups, MTA scores of 0–3 were found and even ratings up to 4 could be seen in the 
oldest age group. 
 
Table 2. Frequency (%) of medial temporal lobe atrophy (MTA) scores in the different age 





MTA 0 MTA 1 MTA 2 MTA 3 MTA 4 
60 yrs 46 51 3 0 0 
66 yrs 36 57 7 0 0 
72 yrs 23 58 18 1 0 
78 yrs 17 56 24 3 0 
81 yrs 4 59 31 6 0 
84 yrs 9 36 46 9 0 
≥87 yrs 1 49 36 11 3 
 
 
A comparison of hippocampal volume/ICV with MTA score (Fig. 7) revealed that there 
was a wide range of volumes for each MTA score and a great variation of MTA scores 
with each volume. As seen in the Figure, there is a great overlap of actual volumes 






































Fig. 7. Scatter plot of normalized hippocampal volume versus medial temporal lobe atrophy 
(MTA). The red line is the association between hippocampal volume and MTA. 
 
Hippocampal volumes normalized to ICV and the inverted MTA score (Fig. 8a and b) 
showed almost parallel curves across the different age groups. The correlation between 
hippocampal volume/ICV and MTA score was highly significant (rs=-0.26, p <0.001, 
on the right side, and rs
 
=-0.32, p <0.001, on the left side) but the correlation coefficient 
was low. The volume of the hippocampus decreased with age, while the MTA score 
increased. Inverting MTA scores on the right vertical axis made the curves easier to 






















































Fig. 8a and b. Left hippocampus/MTA (4a) and right hippocampus/MTA (4b). Scatter plots 
showing normalized hippocampal volume in cm³ (blue) along left Y-axis v.age on X-axis and 
inverted medial temporal lobe atrophy score (red) along right Y-axis v. age. The blue line is the 
association between hippocampal volume and age. The red line is the association between 
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Intra-rater reliability of vaMTA was κ 0.76 on the right side and κ 0.77 on the left side 
in 100 subjects, with weighted kappa (wκ) 0.88 and 0.89, respectively. The ICCs of the 
volumetric measurements were 0.93, according to Zhang et al (39). 
 
When comparing MTA scores from the two different coronal angulations of the 
transverse T1-weighted FFE sequence in 21 subjects by reorienting the images, no 
statistically significant difference in MTA score between the two angulations was 
observed (p=0.69 on the right side and p=1.0 on the left side). Kappa was calculated to 
be κ 0.60 on the right side and κ 0.65 on the left side. Weighted kappa was 0.84 on the 
right side and 0.85 on the left side. 
 
Study III: Two models were created using total hippocampal volume, automated 
regional volume and cortical thickness measurements to compare AD cases with 
controls. The first model, using the total manual hippocampal volume, accounted for 
100% of the variance of the original data (R2(X)) and its cross-validated 
predictability, Q2(Y) = 0.61. The second model, using regional MRI measures, 
resulted in one predictive component with R2(X) = 60% and cross-validated 
predictability Q2(Y) = 0.45. 
 
The separation between patients with AD and controls and the predictive power of the 
models Q2(Y) can be seen in Figure 9a using automated regional volume and cortical 
thickness measurements as input. As can be seen, there is a distinct separation 
between subjects with AD and controls. This model resulted in a prediction accuracy 
of 82.7%. Figure 9b illustrates the variables of importance for distinction between the 
two groups. The pattern of atrophy, including hippocampus, amygdala and entorhinal 
cortex among other temporal lobe regions, together with volume measurements of 
CSF, is similar to previous analyses by the AddNeuroMed cohort using regional MRI 












Fig. 9a and b. OPLS cross validated score plots and MRI measures of importance for the 
separation between AD and CTL. (A) The scatter plot visualises group separation and the 
predictability of the AD vs. CTL model. Each black square represents an AD subject and 
each gray circle a control subject. Control subjects to the left of zero and AD subjects to the 
right of zero are falsely predicted. Q2 (Y).0.05 (statistically significant model). (B) Measures 
above zero have a larger value in controls compared to AD and measures below zero have a 
lower value in controls compared to AD. A measure with a high covariance is more likely to 
have an impact on group separation than a measure with a low covariance. Measures with 
jack knifed confidence intervals that include zero have low reliability. PLoS ONE 
DOI:10.1371/journal.pone.0022506.g003 
 
Visual assessment using the Scheltens scale resulted in a prediction accuracy of 
80.8% and total hippocampal volume yielded a prediction accuracy of 89.1%. In 
summary, the best predictive result was obtained from manual hippocampal measures 
closely followed by the automated image pipeline with OPLS and lastly the visual 
rating assessment. In the investigation of how the three different approaches would 
predict conversion from MCI at baseline to AD at 1 year clinical follow-up, all MCI 
subjects were classified as either AD or control using OPLS models (AD v. CTL). 
The visual assessment for the MCI subjects were performed in the same way, using 
the same cut offs as described previously, resulting in an assessment of abnormal or 
normal brain changes with respect to age. The results demonstrated that 68% of the  
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MCI-c subjects were classified as more AD-like and 68% of the MCI-s subjects were 
classified as more control-like at base line using visual rating. 
 
Using automated regional MRI measures as input to the OPLS model, 74% of the 
MCI-c subjects who converted to AD at 1-year follow-up were predicted to be more 
AD-like and 70% of the MCI-s subjects were predicted to be more control-like at 
baseline. For the total hippocampal volume, 79% of the MCI-c subjects who 
converted to AD at 1-year follow-up were predicted as more AD-like and 54% of the 
MCI-s subjects were predicted to be more control-like. When setting the specificity 
(MCI-s predicted as CTL) to a fixed value (the specificity of the visual assessment) to 
make the comparison of the methods easier, the results were slightly altered.  
 
To conclude, the best results were obtained from the OPLS model with automated 
regional MRI measures as input, with 79% of MCI-c subjects converted to AD at 1-
year follow-up predicted to be more AD-like compared with 68% for the manual 
hippocampal volumes and 68% for Scheltens visual assessment. 
 
Study IV: The distribution of the clinical diagnosis made by the two independent 
geriatricians according to the traditional classification systems was: SCI (n = 18), 
MCI (n = 78), AD (n = 23), VaD (n = 15), FLD (n = 3), unspecified (UNS) dementia 





Fig.10. Flow chart of patients whose files were entered into the dataset for statistical 
analysis. AD = Alzheimer’s disease; FLD = frontal lobe dementia; MCI = mild cognitive 





The concordance between the routine clinical staff who used the results of the 
biomarkers (MRI, SPECT scans and the CSF analyses) in the clinical work-up and 
the study physicians blinded to the biomarkers in question was 90% for the AD 
diagnosis and 66% for all other diagnoses combined. 
 
Our main focus was to investigate the applicability of the Dubois criteria (51) to 
identify possible prodromal AD cases in our clinically diagnosed SCI and MCI 
patients. 
 
A second aim was to validate the Dubois criteria (51) in patients with clinically 
diagnosed AD, according to the traditional diagnostic criteria. For the statistical 
analyses, we therefore excluded the patients with all other clinical dementia diagnoses 
(VaD, FLD and dementia UNS, n = 28) and the three patients who were cognitively 
normal. Thus, 119 patients with SCI, MCI or AD were initially studied. Of these, 
only 110 patients had performed the RAVLT. The majority had had a rating of the 
MTA and CBF done and in about 50% of these patients, analyses of dementia 
biomarkers in CSF were performed (Table 3). 
 
 
Table 3. The frequency of the test performance for patients (n = 150) included in the study. 
 








110 122 117 63 46 54 
 
None of the included patients performed all six tests. Aβ42  = amyloid protein beta 1-42; CBF = 
cerebral blood flow rated using single-photon emission computer tomography (SPECT); CSF = 
cerebrospinal fluid; MTA = medial temporal lobe atrophy; p-tau = phosphorylated tau protein; 
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The normal range and the cut-off values of biomarkers are shown in Table 4. 
 
Table 4. Normal range of biomarkers and the cut-off values used in this study. 
 
BIOMARKERS RANGE PATHOLOGICAL CUT-OFF VALUE 
RAVLT words 0-15 <6 
MTA score 0-4 >2 
CBF score 0-2 >1 
CSF Aβ ng/l >427 <427 
CSF t-tau ng/l >445 >445 
CSF p-tau ng/l <74 >74 
 
Of the 18 patients with the clinical diagnosis of SCI, only three met the core criteria 
set by Dubois. Two of the SCI patients met one additional Dubois criterion, having 
pathological CSF. Thus, compared with the traditional criteria, the Dubois criteria 
could identify two prodromal AD patients among the SCI cases. Similarly, the 
Dubois criteria identified five prodromal AD patients among the 78 MCI patients, 
four of whom had all three additional pathological features and one who had 
pathological CBF.  
 
Among the total number of clinically diagnosed SCI and MCI patients (n = 96), 26% 
(n = 25) met the core criteria of pathological episodic memory levels tested with 
RAVLT but had no additional AD features, according to the Dubois criteria. 
Therefore, ≥1 additional feature identified 7.3% (7/96) “true” prodromal Alzheimer 
cases in the group of 96 clinically non-demented patients.  
 
We also investigated whether the suggested criteria by Dubois et al. (51) could 
identify AD cases in a sample of 23 patients with a clinical diagnosis of AD, 
according to the standard (ICD-10 or DSM-IV) criteria; 95.6% (22/23) patients had a 
pathological episodic memory, while 54.5% (12/22) of them had ≥1 additional AD 
feature. Thus, 54.5% of the patients with an AD diagnosis, according to the 
traditional diagnostic criteria, also met the criteria of Dubois et al (51).  
 
The κ analyses showed a poor to moderate concordance (wκ = 0.18–0.52) between 
the added procedures and biomarkers (RAVLT, MRI, SPECT and CSF) and the 
clinical diagnoses (SCI, MCI and AD). However, delayed recall, objectively assessed 
by RAVLT, was the most sensitive biomarker to detect AD cases (wκ = 0.52). At a 
group level, there were no significant correlations between any of the suggested 
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5 DISCUSSION 
Study I: In parts, the results of this study are as expected. The hypothesis was that both 
intra- and inter-rater kappa values would diverge both with time between investigators 
and from the consensus rating. The results for the general radiologist (KL) supported 
this hypothesis, with decreasing kappa values over the year related to baseline. For the 
neuroradiologist (LC), the kappa decreased to a level of about 0.7 and fluctuated 
around this value over the year, showing a fairly stable evaluation from time point to 
time point.  
 
The difference in experience between the two radiologists may be one explanation for 
this result. Even though the two investigators had been trained together, they did not 
work together and differed greatly in experience. Both had performed vaMTA for about 
2 years prior to this study. However, while the neuroradiologist performed vaMTA 
many times daily, the general radiologist did a few times a week. It is also possible that 
the neuroradiologist had a higher impact on the consensus rating, caused by her greater 
experience. This may be another reason why the general radiologist’s reliability values 
declined over time. 
 
An educational platform in MTA rating, on a department or country basis, may be one 
way of achieving a more reliable assessment. It can be created through a training 
programme including 50–100 cases, iterative training and personal feedback in close 
relation to the assessments. A similar programme, evaluating cardiac CT, is already 
being successfully run at the Department of Radiology of Karolinska University 
Hospital in Stockholm (132). 
 
Our results showed that there were no statistically significant differences when rating 
either of the three T1-weighted sequences, nor different image thickness or angulation 
of images in the coronal plane, used in this study. This means that a reliable assessment 
of MTA is probably not that sensitive to minor changes in technique, concerning MRI 
machines, sequences, coronal angulation and, to some extent, even image thickness. 
 
Study II: The comparison between hippocampal volumes and vaMTA using MTA 
scores showed a highly significant correlation. The correlation coefficient using 
Spearman rank correlation was, however, low (-0.26 Dx, -0.32 Sin), but corresponds to 
that reported in other studies (81). The relatively low, but significant, correlations 
indicate that only a part of the variation in MTA score is explained by the variation in 
total hippocampal volume. There can be a number of possible explanations for this. 
One explanation is that the two methods describe different things. In calculation of the 
volume of the hippocampus, the head, body and tail are outlined manually in every 
MRI scan of the 8 cm long structure. Surroundings are not included in the 
measurement. In vaMTA, only one single coronal image was evaluated. In this method, 
surrounding structures are included in the evaluation, including the temporal horn of 
the lateral ventricle, and the choroid fissure, parahippocampal gyri and collateral and 
parahippocampal sulci (81). This may support the idea that vaMTA assesses whole-
brain atrophy rather than atrophy of the hippocampus (82). A second explanation is that 
when measuring the volume of the hippocampus, atrophy in one part may affect the 
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total volume to a greater or lesser degree, depending on where the changes are located 
in the hippocampus. The vaMTA just tells us what the MTL looks like in one image 
slice, but the primarily affected part may lie somewhere else along the hippocampus. 
 
One possible explanation for the absence of significant side differences with vaMTA is 
that the visual assessment technique may not be sensitive enough to discriminate subtle 
differences. Another possible explanation is that the grading scale has too few rating 
steps in vaMTA. 
 
The normal values of MTA in this study can be of great use in daily clinical practice. 
To know the range of normality in different age groups will be a helpful diagnostic tool 
for geriatricians and neurologists. It is worth mentioning, however, that at the 
individual level the MTA score may be outside the normal range but still be normal. 
 
Study III: Automated computerized MRI methods to aid in the diagnosis of AD will 
only be implemented in clinical practice if they are carefully investigated and 
validated. In this study the overall accuracy was higher for the OPLS technique (83%) 
compared with the visual rating scale (81%) in distinguishing AD cases from 
controls. Although manual measurement of total hippocampal volume still yielded the 
best prediction accuracy (89%), the time-consuming nature of manual measurements 
makes them impractical in a clinical setting. 
 
At 1-year follow-up 19 of the 101 subjects with MCI converted from MCI to AD 
while 82 remained stable. It is, however, difficult to confidently state that one method 
is better than the other due to the small numbers of subjects who converted to AD. 
The three methods predicted 15/19, 14/19 and 13/19 of converters, respectively, to be 
more AD like, which is a small absolute difference that has a larger impact on the 
percentage accuracy. Large studies with longer follow-up times are warranted to 
better investigate this issue. 
 
Although neuropathologically confirmed diagnosis is preferred when evaluating these 
types of automated models, it is very difficult to obtain large neuropathologically 
confirmed datasets in practice. 
 
Neurodegeneration in AD is estimated to start 20–30 years before the clinical 
diagnosis is given (133) and if a diagnosis is to be made at the prodromal stage of the 
disease it may be necessary to combine several different markers of the disease. 
Previously we have shown that combining regional MRI measures with magnetic 
resonance spectroscopy results improves classification results, doubling the positive 
likelihood ratio (134). 
 
Study IV: In our SCI and MCI sample, the Dubois criteria (51) identified only a few 
patients with pre-AD, showing that the traditional classification criteria, at least in our 
sample, are still useful in this heterogeneous patient material. Our sample is a 
naturalistic patient sample from a memory clinic but is highly selective with regard to 
age. This clinic is tasked with investigating all patients with memory disturbances 
<65 years of age in the whole Stockholm region. Consequently, our clinical sample is 
younger than in other memory clinic settings and the proportion of patients with SCI 
   43 
and MCI as compared with patients with dementia is high. The pre-test probability 
for being diagnosed as having AD is therefore lower compared with other clinical 
settings with older patient populations.  
 
The actual pre-AD cases in our sample may be truly low as the use of the Dubois 
criteria suggests here, although the conversion rate of MCI to AD in our clinic after 3 
years’ follow-up (8) is in concordance with international findings. 
 
The rates of conversion from MCI to AD may vary according to age, neuropsycho-
logical profile and the definition of MCI (135, 136). Interestingly, the Dubois criteria 
identified only twelve cases of AD in our sample of 23 patients diagnosed as having a 
dementia syndrome, due to AD, according to the traditional classification 
systems.This may be due to the fact that the traditional criteria takes the evolving 
symptomatology and clinical signs into account, while the new research criteria 
merely focus on episodic memory disturbance and various pathological biomarkers. 
Another reason may be that AD is not just one disease but a heterogeneous group of 
diseases. 
 
One problem with the proposed Dubois criteria (51) is that there are no established 
cut-off levels for dementia biomarkers in CSF. This makes identification of possible 
pre-AD cases in clinical samples vary according to which cut-offs are used. When 
using MTA as a biomarker there is biological variability with age, which has to be 
taken into account for inclusion and for outcome measures in clinical trials (137).Our 
study shows that MTA was normal or only questionably pathological in 82.6% of the 
clinically diagnosed AD patients. A possible interpretation is that our sample was 
younger, with a low degree of global cognitive deficits, and that it may be more 
relevant to measure atrophy in more anterior areas than suggested by the Scheltens 
method (78).Magnetic resonance image scanning and CSF sampling will possibly be 
difficult to apply as part of regular routine in dementia screening in Europe due to 
local regulations and attitudes (138). 
 
All these findings urge us also to focus on the development of other possible 
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6 CONCLUSIONS AND FUTURE ASPECTS 
Visual assessment of MTA has proved to be a fast and reliable method. In this thesis it 
has been shown that the method is reliable over time when performed by a trained 
neuroradiologist. When the method is compared with manual volumetry and automatic 
measurement, MTA rating is not the best method for differentiating between AD cases 
and controls, but the differences between methods are very small. Visual assessment of 
MTA is useful even for predicting conversion from MCI to AD and in this respect it is 
nearly as good as volumetry or automatic multivariate analysis. 
 
When testing the Dubois research criteria from 2007 in a clinical setting our result are 
not in line with results from another retrospective study which showed almost 100% 
agreement between the new research criteria and neuropathology .In our study all 
patients were re-diagnosed and the re-diagnostic work-up was done to avoid all 
circularity bias. In late 2011 the debate was still ongoing whether these new research 
criteria are possible to implement in clinical practice. There is a need for new up-dated 
clinical criteria for AD, but they have to be carefully tested in prospective studies 
especially in the preclinical and asymptomatic stages of the disease, before being 
generally accepted. 
 
Visual assessment of MTA is not a very well-known or well-used method in Sweden. 
In neuroradiology departments it may be heard of (though seldom used), but rarely in 
rural hospitals. At geriatric and neurology departments, however, the method is better 
known, at least in university hospitals. 
 
From a clinical perspective, vaMTA can add important information for the diagnostic 
work-up. The method is fast and can be performed together with the regular neuro-
radiology report. It is possible to use the method on both MRI and CT images, with 
reliable results. It is also possible to compare measures from CT and MRI examinations 
with each other and get comparable results. In our department we use both CT and MRI 
for evaluating atrophy progression and have found it clinically valuable.Taking all this 
into account, it is possible just to use good-quality CT in the investigation of dementia 
especially in the very old. The scanning time is a few seconds and there are only minor 
limitations according to patient co-operation. In the near future we can foresee an 
increasing demand for vaMTA from our colleagues in geriatric and neurology 
departments and as radiologists we have to meet this request with increased knowledge 
about the method. 
 
It is, however, very important to point out that MTA does not give a diagnosis, it just 
visualizes atrophy, and provides no information about the mechanisms behind it. 
 
Even though both manual volumetric measurement of the hippocampus and automatic 
multivariate analysis are slightly better than visual assessment in detecting atrophy, 
they are much more time-consuming. Rating MTA takes a few minutes, while 
volumetry, manually outlined, takes about 40 minutes for two hippocampi. With 
today’s technique, automatic segmentation of the whole brain including both volumes 
and cortical thickness takes around 13 computer hours for between one and eight 
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patients, but then the whole brain is measured and not just the hippocampus. When 
trying to implement automatic segmentation or volumetric measurement in a clinical 
setting today the time-consuming evaluation will be a problem, when great numbers of 
brains need to be investigated daily. 
 
In the future, however, automatic multivariate analysis may be the method of choice 
combined with visual assessment of atrophy of all brain regions. It may be possible to 
use this in the same way as in evaluating SPECT with BRASS. First the radiologist 
performs visual assessment. This is then compared with an automatic method for 
confirmation or for correction. 
 
The BRASS evaluation takes about 5 minutes to perform but much human brainpower 
and computer power has to be used to reduce the evaluating time for multivariate 
analysis to be comparable to BRASS and possible to use in clinical routine assessment. 
Other automatic and semi-automatic methods and techniques are being developed that 
can be used to evaluate different brain volumes and cortical structures and a great deal 
of research in this field is currently underway. 
 
Further new areas for using visual rating scales will be developed, as well. New areas 
for visual rating scales are under development. Recently a rating scale for visual 
assessment of posterior atrophy was published by Koendam et al. Other areas of special 
interests for visual assessment may be the amygdala and entorhinal cortex. A technique 
for visual assessment of atrophy in basal ganglia will also be highly desirable. 
 
New AD- and dementia-biomarkers are under development and right know focus is 
primarily in finding biomarkers in the blood. To calculate gene expression in blood test 
may be a further way to identify patients with high likelihood of having AD or other 
dementias. 
 
The use of PET-PIB and other new PET markers will definitely increase in the future in 
early assessment of AD. At the moment, PET-PIB is, however, only available for 
research purposes. It is still too expensive for clinical use and also there are too few 
PET cameras today to meet the increasing demand for this method in Sweden. 
 
In the meantime, until such problems are solved, vaMTA and visual assessment of 
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